**Supplementary table 1.** Results of EudraCT clinical trial registry search

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **EudraCT number** | **Title of trial** | **Trial initiator** | **Start date** | **Status** | **Reported outcome** |
| 2010-023883-42 | Randomized, double-blind, placebo controlled trial to evaluate the efficacy of high dose intravenous immunoglobulins in diabetic painful polyneuropaty (DPNP) resistant to conventional therapies | A.O. DI RILIEVO NAZIONALE (non-commercial) | 2012-03-28 | Prematurely ended; no date given | Not reported |
| 2010-023963-16  NCT01540630 | A Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Safety and Efficacy of CNV1014802 in Patients with Trigeminal Neuralgia | Convergence Pharmaceuticals Ltd  (commercial) | 2012-01-05 | Completed 2014-02-26 | Primary efficacy endpoint: no statistically significant difference to placebo1 |
| 2011-005879-16 | A Phase II, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Neuropathy | Glenmark Pharmaceuticals SA (commercial) | 2012-06-11 | Never initiated | No patients recruited |
| 2012-000058-73 | A multi-centre (UK) double-blind randomised parallel group placebo controlled trial to evaluate the efficacy, safety, and tolerability of Intravenous Immunoglobulin (IVIg) 0.5g/kg plus standard treatment, versus matched placebo plus standard treatment in patients with longstanding Complex Regional Pain Syndrome. | University of Liverpool (non-commercial) | 2012-09-14 | Completed 2016-03-19 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2012-000347-28  NCT01752322 | Efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain | Grünenthal GmbH (commercial) | 2012-09-03 | Completed 2016-06-21 | Primary efficacy endpoint: no statistically significant difference to placebo2 |
| 2012-000399-41 | An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with postherpetic neuralgia (PHN). | Laboratorios del Dr. Esteve. S.A. (commercial) | 2012-07-23 | Study patients could not be recruited at a reasonable rate, the sponsor prematurely terminated the study after a period of 12 months recruitment, with 13 patients randomized. | Results provided but limited by low subject number |
| 2012-000400-14 | An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with painful diabetic neuropathy. | Laboratorios del Dr. Esteve. S.A. (commercial) | 2012-06-14 | Completed 2014-12-04 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2012-000402-30 | An exploratory, randomized, double blind, placebo controlled, parallel groups Phase II clinical trial to evaluate the efficacy and safety of E-52862 (400 mg) by oral route, in patients with post-surgical neuropathic pain. | Laboratorios del Dr. Esteve. S.A. (commercial) | 2012-06-18 | Completed 2014-12-03 | Primary efficacy endpoint: superiority to placebo |
| 2012-001540-22  NCT01699854 | CAPSAICIN PATCH 8% FOR THE TREATMENT OF PERSISTENT PAIN AFTER INGUINAL HERNIOTOMY | Mads Werner (non-commercial) | 2012-06-27 | Completed 2013-09-30 | Primary efficacy endpoint: no statistically significant difference to placebo3 |
| 2012-002240-24  NCT01678924 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Safety and Efficacy of a Single Treatment of AGN-214868 in Patients With Postherpetic Neuralgia | Allergan Ltd (commercial) | 2013-02-28 | Prematurely ended 2015-09-30 | Primary efficacy endpoints: no statistically significant differences to placebo |
| 2012-002320-33 | A Phase 2, 4 Week Randomized, Double-Blind, Parallel Group, Placebo Controlled Proof of Concept Study to Evaluate Efficacy, Safety and Tolerability of GRC 17536 in Patients with Painful Diabetic Peripheral Neuropathy | Glenmark Pharmaceuticals SA (commercial) | 2012-09-27 | Completed 2014-07-23 | Primary efficacy endpoint:  No p values provided |
| 2012-002903-16 | A randomised, double-blind, crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in patients with post-herpetic neuralgia | Convergence Pharmaceuticals Ltd (commercial) | 2013-04-08 | Completed 2014-02-06 | Not reported |
| 2012-003304-12 | A Randomized Double Blind Placebo Controlled Parallel Group Study of the Efficacy and Safety of Pregabalin (BID) in Subjects with Post-Traumatic Peripheral Neuropathic Pain | Pfizer Inc (commercial) | 2013-02-12 | Completed 2015-08-4 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2012-005328-14 | Effect of Sativex on neuropathic pain and spasticity following spinal cord injury | Spinal Cord Injury Centre of Western Denmark (non-commercial) | 2013-04-16 | Prematurely ended 2014-07-02 | Not reported |
| 2012-005590-32 | A double blind, placebo controlled Phase 2 study comparing the effects of ARA 290 on neuropathic symptoms of patients with type 2 diabetes | Leiden University Medical Center (non-commercial) | 2013-02-20 | Ongoing | Not reported |
| 2013-000407-16 | A randomised three week double-blind crossover study to compare the efficacy and safety of CNV2197944 75 mg tid versus placebo in the treatment of neuropathic pain in patients with diabetic peripheral neuropathy | Convergence Pharmaceuticals Ltd (commercial) | 2013-07-24 | Completed 2014-06-30 | Not reported |
| 2013-000521-31 | Efficacy and safety of gabapentin versus placebo to prevent the incidence of PostHerpetic Neuralgia | Gerencia de Atención Primaria de Mallorca (non-commercial) | 2013-12-26 | Completed 2016-12-16 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2013-001511-70 | Efficacy, safety and tolerability of lacosamide in patients with gain-of-function Nav1.7 mutations related small fiber neuropathy: a randomized, double-blind, placebo controlled, crossover trial | Maastricht University Medical Center (non-commercial) | 2015-08-05 | Completed, no date given | Not reported |
| 2013-002521-27  NCT02065349 | A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain | Astellas Pharma Europe B.V. (commercial) | 2014-05-08 | Completed 2015-02-13 | Primary efficacy endpoint: no statistically significant difference to placebo  A futility analysis of the responder rate, based on the FAS1, was performed by Astellas after first 75 participants completed or discontinued from the single-blind period. Test results confirmed study did not meet futility criterion. |
| 2013-003016-45 | A double blind, placebo controlled Phase 2 dose ranging study of the effects of ARA 290 on corneal nerve fiber density and neuropathic symptoms of patients with sarcoidosis | Araim Pharmaceuticals (non-commercial) | 2013-09-11 | Completed 2015-02-02 | Primary efficacy endpoint:  statistically significant difference to placebo for one dose regimen of the trial medication4 |
| 2013-003968-31 | A phase II RCT of topical menthol gel versus placebo in the treatment of chemotherapy induced peripheral neuropathic pain | University of Edinburgh (ACCORD) (non-commercial) | 2014-04-09 | GB - no longer in EU/EEA | No results available |
| 2013-004876-37 | A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain of diabetic origin treated with pregabalin or gabapentin | Pharmaleads SA (commercial) | 2014-03-31 | Prematurely ended 2016-03-09 | Not reported |
| 2014-005035-13 | GaPP 2: A multi-centre randomised controlled trial of the efficacy and mechanism of action of gabapentin for the management of chronic pelvic pain in women | University of Edinburgh and NHS Lothian (non-commercial) | 2015-02-13 | Completed 2019-10-31 | Primary efficacy endpoints: no statistically significant differences to placebo |
| 2014-005344-17 | Oral cannabidivarin (CBDV) solution for treatment of HIV-associated neuropathic pain – a randomized, double-blind, placebo-controlled phase II study. | Department of Anesthesiology and Operative Intensive Care Medicine, Charité (CBF) (non-commercial) | 2015-08-21 | Completed 2020-01-15 | Primary efficacy endpoint: no statistically significant difference to placebo5 |
| 2014-005656-26 | Amitriptyline 10% and ketamine 10% cream in neuropathic pain: A randomised, double-blind, placebo-controlled cross-over pilot study with a three months open follow-up | Westfriesgasthuis (non-commercial) | 2015-10-14 | Ongoing | Not reported |
| 2015-000263-14 | Mycophenolate Treatment for Longstanding Complex Regional Pain Syndrome (MYPS I) | Walton Centre NHS Foundation Trust | 2015-04-27 | GB - no longer in EU/EEA | No results available |
| 2015-001136-37 | A randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy, safety and tolerability of CR4056 administered for 2 weeks in patients with osteoarthritis of the knee with moderate to severe chronic pain (with or without a neuropathic component) | Rottapharm Biotech S.r.l. (commercial) | 2015-08-19 | Completed 2016-07-05 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2015-001195-21  NCT02490436 | NoTOPain Novel Treatment Option for neuropathic Pain A randomized, cross-over, placebo-controlled, double-blind, single-center, phase II study of cetuximab in patients with treatment-refractory, non-malignant severe chronic neuropathic pain. | Sørlandet Hospital (non-commercial) | 2015-10-19 | Ongoing  Posted as completed Oct 2016 in ClinTrial.gov | Not reported  Paper available6 |
| 2015-001523-24 | Evaluation of the analgesic effects of prolonged-release oxycodone and of L-Dopa, versus placebo, on central neuropathic pain in Parkinson's disease : OXYDOPA trial | UHToulouse (non-commercial) | 2016-03-25 | Prematurely ended 2020-11-17 | Not reported |
| 2015-001769-14 | Analgesic efficacy of intravenous lacosamide administered perioperatively for thoracic surgery with thoracotomy approach | Javier E. Morales Sarabia (non-commercial) | 2017-02-13 | Ongoing | Not reported |
| 2015-002624-31 | Intravenous immunoglobulin therapy for small fiber neuropathy: a randomised, double-blind, placebo-controlled study on efficacy and safety | Maastricht UMC (non-commercial) | 2015-12-23 | Ongoing | Not reported |
| 2015-002984-40 | The beta-2-agonist terbutaline for the treatment of painful polyneuropathy. A randomised, active- and placebo-controlled trial | Department of Neurology, Odense University Hospital (non-commercial) | 2015-09-25 | Completed 2019-04-29 | Primary efficacy endpoint: no statistically significant difference to placebo7 |
| 2015-004775-78  NCT02935608 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIIB074 in Subjects With Neuropathic Pain From Lumbosacral Radiculopathy | Biogen Idec Research Limited (commercial) | 2016-05-09 | Completed in most countries; globally ended 2018-08-06 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2015-004779-64  NCT02957851 | Equimolar Mixture of Oxygen and Nitrous Oxide (EMONO) for the Treatment of Peripheral Neuropathic Pain: a Randomised, International, Multicentre, Placebo-Controlled, Phenotype-stratified Phase IIa Study | Air Liquide Santé International (commercial) | 2016-12-20 | Completed 2018-08-30 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2015-005601-37  NCT02763592 | IMPACT OF 5% LIDOCAINE MEDICATED PLASTER ON ALLODYNIC SYMPTOMS OF LOCALIZED NEUROPATHIC PAIN AFTER KNEE SURGERY. A prospective, randomized, placebo controlled study in parallel groups. | CHU Clermont-Ferrand (non-commercial) | 2016-02-24 | Completed; date not given | Primary efficacy endpoint: statistically significant difference to placebo8 |
| 2015-005786-23 | A phase I/IIa, randomized, double-blind, single-dose, placebo controlled, two-way crossover clinical trial to assess the safety and to obtain efficacy data in intrathecal administration of expanded Wharton jelly mesenchymal stem cells in chronic traumatic spinal cord injury | Banc de Sang i Teixits (non-commercial) | 2016-04-20 | Ongoing | Not reported |
| 2016-000280-16  NCT03094195 | A double-blind, placebo-controlled, randomized dose ranging trial to determine the safety and efficacy of three dose levels of EMA401 in reducing 24-hour average pain intensity score in patients with post-herpetic neuralgia (EMPHENE) | Novartis Pharma AG (commercial) | 2017-05-16 | Terminated early due to preclinical toxicity data 2019-03-07 | Primary efficacy endpoint: no statistically significant difference to placebo9 |
| 2016-000281-39  NCT03297294 | A double-blind, placebo-controlled, randomized trial to determine the safety and efficacy of EMA401 in reducing 24-hour average pain intensity score in patients with painful diabetic neuropathy (EMPADINE) | Novartis Pharma AG (commercial) | 2018-03-08 | Terminated early due to preclinical toxicity data 2019-03-25 | Primary efficacy endpoint: no statistically significant difference to placebo9 |
| 2016-000864-41 | A randomized controlled trial of lidocaine patch for lower limb amputation pain. | Centre Hospitalier Universitaire Brugmann (non-commercial) | 2016-06-02 | Terminated 2019-09-05 | No patients recruited |
| 2016-001449-16 | A Phase 3 Placebo-Controlled, Double-Blind Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Subjects With Trigeminal Neuralgia | Biogen Idec Research Limited (commercial) | 2017-04-11 | Ongoing | Not reported |
| 2016-002772-27  NCT03202979 | Efficacy and safety of low doses of trazodone in patients affected by painful diabetic neuropathy: randomized, controlled, pilot study. | Angelini S.p.A. (commercial) | 2017-03-20 | Completed 2018-08-09 | Primary efficacy endpoint: no statistically significant difference to placebo10 |
| 2016-002846-21 | CLINICAL TRIAL PHASE IIa PROOF OF CONCEPT, DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED IN PATIENTS WITH NEUROPATHIC PAIN DUE TO PERIPHERAL NERVE INJURY | BCN Peptides S.A. (commercial) | 2017-04-10 | Prematurely ended 2018-11-19 | Not reported |
| 2017-000991-27  NCT03339336 | A Phase 2 Placebo-Controlled, Double-Blind, Enriched Enrollment Randomized Withdrawal Study to Evaluate the Efficacy and Safety of BIIB074 (Vixotrigine) in Treating Pain Experienced by Subjects With Confirmed Small Fibre Neuropathy That Is Idiopathic or Associated With Diabetes Mellitus | Biogen Idec Research Limited (commercial) | 2018-02-27 | Prematurely ended; one country completed; globally ended 2021-04-12 | Not reported |
| 2017-002320-25 | Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS | UNICANCER (non-commercial) | 2018-07-03 | Ongoing | Not reported |
| 2017-003054-16 | Randomized double-blind, placebo-controlled parallel group study over 12 months to assess the effects of treatment with benfotiamine on morphometric, neurophysiological, and clinical measures in type 2 diabetes patients with mild to moderate symptomatic polyneuropathy - BOND Study | Wörwag Pharma GmbH & co. KG (commercial) | 2018-07-27 | Restarted | Not reported |
| 2017-003369-85 | A multicenter, double-blind, randomized, placebo-controlled, parallel-group study to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease | Idorsia Pharmaceuticals Ltd (commercial) | 2018-05-14 | Completed in most countries, globally ended 2021-09-02 | Not reported |
| 2017-003930-10  NCT03513822 | KETAMINE'S EFFICIENCY IN THE TREATMENT OF CHRONIC PAIN WITH INFLAMMATORY COMPONENT: EXPLORING THE KYNURENIN PATHWAYS. A controlled, placebo-controlled, double-blind trial. | Recherche et enseignement en douleur, Anesthesie Réanimation (non-commercial) | 2018-01-12 | Ongoing | Not reported |
| 2017-005198-38 | Tetra-hydro-cannabinol, cannabidiol and their combination for the treatment of peripheral neuropathic pain. A randomised placebo-controlled trial | Odense University Hospital (non-commercial) | 2018-10-26 | Completed 2021-05-03 | Not reported |
| 2018-000133-12  NCT03749642 | Efficacy and safety of Fixed-Dose Combination (FDC) products containing trazodone and gabapentin in patients affected by painful diabetic neuropathy: randomized, controlled, dose finding study | Angelini S.p.A. (commercial) | 2018-10-26 | Completed 2020-06-06 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2018-001703-37  NCT03663101 | A double-blind, randomised, placebo controlled, proof-of-concept study in subjects with abdominal or thoracic chronic scar pain to assess the analgesic properties of intradermal doses of Dysport® | Ipsen Innovation SAS (commercial) | 2018-09-06 | Recruitment was closed prematurely due to slow enrolment by2019-06-30 | No statistical analyses for primary efficacy endpoints provided |
| 2018-002315-98 | The effect of medical cannabis on neuropathic pain and spasticity in patients with Multiple Sclerosis and in patients with spinal cord injury. A multicenter national placebo-controlled trial | Aarhus Universitetshospital (non-commercial) | 2018-12-06 | Restarted | Not reported |
| 2018-002523-42 | A randomised, double-blind, placebo-controlled, dose-response study of the efficacy and safety of MEDI7352 in subjects with painful diabetic neuropathy | AstraZeneca AB (commercial) | 2018-10-22 | Ongoing | Not reported |
| 2018-003110-40  NCT03777956 | The effect of lacosamide in peripheral neuropathic pain: a randomized, double-blind, placebo-controlled, phenotype-stratified study | Aarhus University (non-commercial) | 2018-09-11 | Ongoing | Not reported |
| 2018-004534-15  NCT03865953 | A Phase IIa study of the efficacy and safety of oral LAT8881 in neuropathic pain | Lateral Pharma Pty Ltd (commercial) | 2019-09-03 | Completed 2020-05-04 | Primary efficacy endpoint: no statistically significant difference to placebo |
| 2018-004792-13  NCT04148573 | A randomized, double-blind, placebo controlled, parallel group, multicentric, phase IIa clinical trial to evaluate the safety, tolerability and therapeutic efficacy of daily oral treatment with NFX88 on neuropathic pain in patients with spinal cord injury. | Neurofix S.L. (commercial) | 2019-05-23 | Ongoing | Not reported |
| 2019-000243-27 | The effect of bupropion in peripheral neuropathic pain. A randomized, double-blind, placebo-controlled study | Odense University Hospital (non-commercial) | 2019-03-18 | Ongoing | Not reported |
| 2019-000848-95 | A Placebo-Controlled, Double-Blind, Randomized, Proof-of-Concept Study to Evaluate the Efficacy and Tolerability of Erenumab in Patients with Trigeminal Neuralgia | Dansk Hovedpine Center, Neurologisk Klinik, Rigshospitalet – Glostrup (non-commercial) | 2019-07-29 | Completed 2021-09-13 | Not reported |
| 2019-003502-28 | A Randomized, Double-blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of AP-325 in Subjects with Peripheral Post-surgical Neuropathic Pain | Algiax Pharmaceuticals GmbH (commercial) | 2020-02-14 | Ongoing | Not reported |
| 2020-000107-36 | Proof of efficacy, maintenance of efficacy, long-term safety and investigation of the potential for dependence and abuse and the effect of abrupt drug withdrawal of VER-01 in a multicenter study in the treatment of patients with chronic non-specific low back pain | Vertanical GmbH (commercial) | 2021-03-24 | Ongoing | Not reported |
| 2020-001340-25 | Enrichment randomized double-blind, placebo-controlled cross-over trial with PHEnytoin cream in patients with painful chronic idiopathic axonal polyNEuropathy | University Medical Center Utrecht (non-commercial) | 2020-07-17 | Ongoing | Not reported |
| 2020-002066-14  NCT04641273 | A randomized, placebo-controlled, double-blind, parallel-group, multicenter combined Phase 2a/2b study to assess the efficacy and safety of BAY 1817080 in patients with diabetic neuropathic pain | Bayer AG (commercial) | 2020-12-30 | Prematurely ended  Globally ended 2021-12-17 | Not reported |
| 2020-002609-24 | A Randomized, Double-blind, Placebo-Controlled, Multicenter, Phase 3 Clinical Study to Evaluate Efficacy and Safety of the Once-Daily Extended-Release Pregabalin and the Immediate-Release Pregabalin in Peripheral Neuropathic Pain | Laboratorios Lesvi, S.L. (Neuraxpharm group) (commercial) | 2021-05-17 | Ongoing | Not reported |
| 2021-001392-17  NCT05219812 | A randomized, double-blind, cross-over, placebo-controlled, multi-center, Phase 2a study to assess the safety and efficacy of BAY 2395840 in patients with diabetic neuropathic pain | Bayer AG (commercial) | 2022-01-03 | Ongoing | Not reported |
| 2021-002350-90  NCT05206773 | A randomized, double-blind, placebo-controlled, 12 month Phase 3 study to evaluate the effect of venglustat on neuropathic and abdominal pain in male and female adults with Fabry disease who are treatment-naïve or untreated for at least 6 months | Sanofi-Aventis Recherche & Développement (commercial) | 2022-4-01 | Ongoing | Not reported |

Search with ‘neuropathic pain’, ‘adult’, ‘phase 2 and 3’, ‘start date 2012-01-01 to 2022-02-21’ resulted in 104 trials; this database was then searched for randomised placebo-controlled trials. Additionally, 2 trials were picked up from the ClinicalTrials.gov database search.

1 [Zakrzewska](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Zakrzewska+JM&cauthor_id=28216232) JM, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 16, 291-300 (2017).

2 Palladini M, et al. Lidocaine medicated plaster, an additional potential treatment option for localized post-surgical neuropathic pain: efficacy and safety results of a randomized, placebo-controlled trial. Curr Med Res Opin. 35, 757-766 (2019).

3 Bishoff JM, et al. A capsaicin (8%) patch in the treatment of severe persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled trial. PLoS One. 9(10):e109144 (2014).

4 Culver DA, et al. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain. Invest Ophthalmol Vis Sci. 58, BIO52–BIO60 (2017).

5 [Eibach](https://pubmed.ncbi.nlm.nih.gov/?sort=date&term=Eibach+L&cauthor_id=32770831) L, et al. Cannabidivarin for HIV-Associated Neuropathic Pain: A Randomized, Blinded, Controlled Clinical Trial. Clin Pharmacol Ther.109, 1055-1062 (2021).

6 Kersten C, et al. Relief of Neuropathic Pain Through Epidermal Growth Factor Receptor Inhibition: A Randomized Proof-of-Concept Trial. Pain Med. 20, 2495-2505 (2019).

7 Gillving M, et al. A randomized, controlled trial of a β2-agonist in painful polyneuropathy. Pain. 162, 1364-1373 (2021).

8 Pickering G, et al. Effectiveness and safety of 5% lidocaine-medicated plaster on localized neuropathic pain after knee surgery: a randomized, double-blind controlled trial. Pain. 160, 1186-1195 (2019).

9 Rice AS, et al. [Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. Pain. 162, 2578-2589 (2021).](https://clinicaltrials.gov/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFRcgF8cRFjA6h9Ei4L3BUgWwNG0it.)

10 Lipone P, et al. Efficacy and Safety of Low Doses of Trazodone in Patients Affected by Painful Diabetic Neuropathy and Treated with Gabapentin: A Randomized Controlled Pilot Study. CNS Drugs. 34, 1177-1189 (2020).